VRAXNasdaqIn Vitro & In Vivo Diagnostic SubstancesFiscal year ends March 31

Virax Biolabs Group Ltd

Financials through fiscal 2026, year ended Mar 31, 2026Last filing: 20-F on Jul 6, 2026

$1.40−0.05 (-3.45%)

Close on Oct 19, 2026

Market cap: –
P/E (TTM): –
Dividend yield: –

Virax Biolabs Group Ltd income statement

AnnualQuarterlyTTM

Millions of USD, except per-share data. Shares in millions.

Line item	FY 2026 2026-03-31	FY 2025 2025-03-31	FY 2024 2024-03-31	FY 2023 2023-03-31	FY 2022 2022-03-31	FY 2021 2021-03-31
Revenue	0.01	0.01	0.16	0.01	0	0.12
Cost of Revenue	0.00	0.06	0.11	0.01	–	0.13
Gross Profit	0.01	-0.05	0.05	0.00	–	-0.01
Research & Development	3.74	2.03	1.61	2.18	0.43	0.12
Operating Expenses	6.41	6.02	6.58	5.73	1.73	0.64
Operating Income	-6.40	-6.08	-6.53	-5.73	-1.73	-0.64
Pretax Income	-5.93	-6.20	-6.74	-5.46	-1.75	-0.67
Income Tax Expense	-0.90	-0.14	0	–	–	–
Net Income incl. Noncontrolling Interests	-5.03	-6.07	-6.74	-5.46	-1.75	-0.67
Minority Interest in Earnings	-0.01	-0.01	-0.01	0.00	-0.04	-0.02
Net Income	-5.02	-6.06	-6.73	-5.46	-1.71	-0.65
EPS (Basic)(per share)	-12.64	-40.62	-83.90	-128.25	-44.75	–
EPS (Diluted)(per share)	-12.64	-40.62	-83.90	-128.25	-44.75	–
Shares Outstanding (Basic, Weighted)(shares)	0.40	0.15	0.08	0.04	0.04	0.02
Shares Outstanding (Diluted, Weighted)(shares)	0.40	0.15	0.08	0.04	0.04	0.02
EBITDA	–	-5.81	-6.47	–	–	–

Italic numbers are calculated by StockData (for example Q4 = full year − nine months). Per-share data and share counts are adjusted for stock splits. Hover a number for its source; click it to open the filing on SEC.gov. Click a row to chart it.

Ratios

Latest available, balances at Mar 31, 2026

Profitability, FY2026

Gross margin: 61.9%
Operating margin: -51515.2%
Net margin: -40439.1%
Return on equity, FY2026: -75.7%

Financial strength

Current ratio: 9.97
Debt to equity: –
Debt to assets: –
Cash to current liabilities: 940.0%

Valuation

P/E ratio: –
Price to sales: –
Price to book: –
Dividend yield: –